CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
INCB018424drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03697460
NCT03697460Phase 2Completed
CompareCT.gov

INCB018424 in the Treatment of Cutaneous Lichen Planus

Aaron R. Mangold·interventional·Posted Oct 5, 2018·Updated Aug 4, 2021

In Brief

A Phase 2 clinical trial evaluating INCB018424 for Lichen Planus. Completed, enrolled 12 participants across 1 site.

Detailed Summary

To evaluate the safety and efficacy of INCB018424 PHOSPHATE CREAM in cutaneous LP as assessed by the change in Physician Global Assessment (PGA), Body Surface Area (BSA), Index Treatment and Control Lesion by Clinical Assessment Scale of Severity for Index Lesion Signs and Symptoms (CAILS) score, Pruritus Numerical Rating Scale (NRS), and Skindex-16. To predict responses through the identification of unique biomarkers of LP at week 0 and utilizing RNA sequencing on responsive and non-responsive tissue at week 4.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLichen Planus
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 5, 2018
Enrollment StartAug 30, 2018
Primary CompletionJun 25, 2020
Study CompletionAug 25, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.7 years ago

Interventions

INCB018424drug

INCB018424 PHOSPHATE CREAM 1.5%, topical application, twice daily on lesions of cutaneous LP.